Xylem, Liberty Latin America, Saga Communications, Telefonica Brasil, Terns Pharma, NICE: Analyst Ratings and Price Targets Hint at Potential Upsides
- June 01st, 2023
- 674 views
Xylem Inc. (NYSE: XYL) has received an upgrade from Neutral to Outperform by Robert W. Baird, with the price target raised from $122 to $135.
On Wednesday, $XYL closed at $100.20, indicating a potential upside of $34.80 or 34.72% based on the analyst's view.
Liberty Latin America Ltd. (Nasdaq: LILA) has been initiated with a Buy rating by Goldman Sachs, with a price target of $10.
With $LILA closing at $7.32 on Wednesday, this suggests a potential upside of $2.68 or 36.61% according to Goldman Sachs' assessment.
Saga Communications, Inc. (Nasdaq: SGA) has been initiated with an Outperform rating by Noble Capital Markets, setting the price target at $27.
On Wednesday, $SGA closed at $19.50, indicating a potential upside of $7.50 or 38.46% based on Noble Capital Markets' evaluation.
Telefônica Brasil S.A. (NYSE: VIV) has been initiated with a Buy rating by Goldman Sachs, with a price target of $10.
With $VIV closing at $7.92 on Wednesday, this implies a potential upside of $2.08 or 26.26% based on Goldman Sachs' view.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) has been initiated with a Buy rating by ROTH MKM, setting the price target at $23.
On Wednesday, $TERN closed at $10.61, suggesting a potential upside of $12.39 or 116.84% according to ROTH MKM's analysis.
NICE Ltd. (Nasdaq: NICE) has been initiated with a Buy rating by Mizuho, with a price target of $244.
With $NICE closing at $205.94 on Wednesday, this implies a potential upside of $38.06 or 18.47% based on Mizuho's assessment.
Please note that the potential upsides mentioned for each company are based on the views and evaluations of the respective brokerage firms, investment groups, or analysts mentioned. Investors should carefully consider these analyses and conduct their own research before making any investment decisions.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025




Member Login